CG Oncology reports FY2024 net loss $88.0M; cash $742M; cretostimogene CR rate 75.5%

CG Oncology, Inc.

Net loss attributable to common stockholders $88.0M ($1.41/share) vs $67.8M ($15.65/share) in FY2023.
Cash and marketable securities $742.0M as of Dec 31, 2024; $238M oversubscribed equity offering extends runway to H1 2028.
Cretostimogene monotherapy achieved 75.5% complete response rate in BOND-003; median DoR exceeds 28 months.
R&D expenses $82.1M in FY2024 (up from $45.8M); G&A expenses $33.7M (up from $9.9M).
BLA submission for cretostimogene in HR BCG-unresponsive NMIBC anticipated H2 2025; CORE-008 topline data expected H2 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-046335
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2025-03-28T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.725623+00:00
generated_at: 2026-05-24T03:25:55.500954+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-046335
json_url: https://secwatch.observer/filing/0000950170-25-046335.json
markdown_url: https://secwatch.observer/filing/0000950170-25-046335.md
text_url: https://secwatch.observer/filing/0000950170-25-046335.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/0000950170-25-046335-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-20250328.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-046335

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.